Intelligent transit box keeps vaccinations cool

Vaccination supplies can be rendered useless if their temperature rises above the permitted maximum. MEDICASE has developed an intelligent transit box which ensures tight temperature control and which has a built-in data logger to provide a temperature audit trail.

Research shows that a surprising proportion of medical supplies and samples become damaged during transit. This represents a serious problem both for supplier and end users. A customer recently received a consignment of vaccinations worth millions of euros, which turned out to be denatured. The damage arose because the plane carrying the consignment had had to wait a long time on the runway, and this had caused an unacceptable rise in temperature.

"It doesn’t take long for a vaccine to become useless if the ambient temperature rises to 20-25° Celsius," explains Colin Rickson of Kryotrans, and head of MEDICASE exploitation. "The conventional solution is to use packaging made from expanded polystyrene and cardboard, but these can only maintain the temperature for a limited period and are difficult to dispose of."

Part of the problem with conventional packaging is that the end user can't be certain that the temperature limits have been exceeded. "When meningitis vaccinations were given to high-risk groups in Wales several years ago, it was subsequently found that over half had not received protection. The cause was traced to overheating of the vaccines in transit," adds Rickson.

The MEDICASE reusable transit box maintains temperature for up to seven days, and has a built-in data logger that records both inside and ambient temperature. Also, because the boxes are reusable, the thermal insulation characteristics can be improved without the environmental impact that disposable boxes carry. "We've also developed a version that can tell you what country it's in and what the temperature is," says Rickson. "It has, in addition to the data logger, a built-in GPS satellite navigation receiver and GSM mobile phone for communications."

"We anticipate that the consortium will start production of the units will early in 2005," says Rickson. "We shall be exhibiting fully operational pre-production prototypes at the IST 2004 event at The Hague [15-17 November 2004]."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine